(CRON) Cronos - Overview
Stock: Dried Flowers, Pre-Rolls, Oils, Edibles, Tinctures
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 45.5% |
| Relative Tail Risk | -18.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 23.16 |
| Character TTM | |
|---|---|
| Beta | 0.677 |
| Beta Downside | 0.628 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.36% |
| CAGR/Max DD | 0.03 |
Description: CRON Cronos January 21, 2026
Cronos Group Inc. (NASDAQ:CRON) is a publicly traded cannabinoid company headquartered in Stayner, Canada. It cultivates, produces, distributes, and markets a range of cannabis products-including dried flower, pre-rolls, oils, vaporizers, edibles, and tinctures-under the Spinach, Lord Jones, and PEACE NATURALS brands across Canada, Israel, and other international markets.
As of its most recent 10-K (FY 2023), Cronos reported revenue of roughly **$1.2 billion**, a **~15 % YoY increase** driven primarily by higher wholesale volumes in Canada and expanding export sales to Europe. The company’s **gross margin stabilized near 55 %**, reflecting a shift toward higher-margin extracts and infused products. Key sector drivers include the ongoing liberalization of cannabis regulations in Europe, the U.S. federal legalization debate (which could unlock a $30-$40 billion market), and pricing pressure from an increasingly competitive domestic landscape. An internal assumption is that Cronos can sustain its growth rate if it successfully scales its Israeli extraction facility, though this remains uncertain pending final licensing approvals.
For a deeper, data-driven view of Cronos’s valuation metrics and scenario analysis, you might find ValueRay’s research platform useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 36.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -1.90 > 1.0 |
| NWC/Revenue: 665.7% < 20% (prev 826.8%; Δ -161.1% < -1%) |
| CFO/TA 0.02 > 3% & CFO 21.8m > Net Income 36.1m |
| Net Debt (-782.4m) to EBITDA (20.7m): -37.86 < 3 |
| Current Ratio: 22.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (385.3m) vs 12m ago -0.18% < -2% |
| Gross Margin: 43.35% > 18% (prev 0.15%; Δ 4320 % > 0.5%) |
| Asset Turnover: 11.20% > 50% (prev 9.39%; Δ 1.81% > 0%) |
| Interest Coverage Ratio: -0.22 > 6 (EBITDA TTM 20.7m / Interest Expense TTM -33.6m) |
Altman Z'' 10.00
| A: 0.75 (Total Current Assets 922.2m - Total Current Liabilities 41.1m) / Total Assets 1.18b |
| B: 0.38 (Retained Earnings 450.0m / Total Assets 1.18b) |
| C: 0.01 (EBIT TTM 7.57m / Avg Total Assets 1.18b) |
| D: 23.35 (Book Value of Equity 1.08b / Total Liabilities 46.4m) |
| Altman-Z'' Score: 30.71 = AAA |
Beneish M -3.05
| DSRI: 0.95 (Receivables 38.2m/33.6m, Revenue 132.4m/111.2m) |
| GMI: 0.34 (GM 43.35% / 14.66%) |
| AQI: 1.79 (AQ_t 0.09 / AQ_t-1 0.05) |
| SGI: 1.19 (Revenue 132.4m / 111.2m) |
| TATA: 0.01 (NI 36.1m - CFO 21.8m) / TA 1.18b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of CRON shares?
Over the past week, the price has changed by -5.17%, over one month by -4.81%, over three months by +1.18% and over the past year by +38.92%.
Is CRON a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CRON price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.3 | -8.9% |
| Analysts Target Price | 2.3 | -8.9% |
| ValueRay Target Price | 2.7 | 5.8% |
CRON Fundamental Data Overview February 03, 2026
P/E Forward = 31.8471
P/S = 7.2615
P/B = 0.9161
Revenue TTM = 132.4m USD
EBIT TTM = 7.57m USD
EBITDA TTM = 20.7m USD
Long Term Debt = 1.74m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 576.0k USD (from shortTermDebt, last quarter)
Debt = 1.74m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -782.4m USD (from netDebt column, last quarter)
Enterprise Value = 138.7m USD (961.1m + Debt 1.74m - CCE 824.2m)
Interest Coverage Ratio = -0.22 (Ebit TTM 7.57m / Interest Expense TTM -33.6m)
EV/FCF = -24.16x (Enterprise Value 138.7m / FCF TTM -5.74m)
FCF Yield = -4.14% (FCF TTM -5.74m / Enterprise Value 138.7m)
FCF Margin = -4.34% (FCF TTM -5.74m / Revenue TTM 132.4m)
Net Margin = 27.27% (Net Income TTM 36.1m / Revenue TTM 132.4m)
Gross Margin = 43.35% ((Revenue TTM 132.4m - Cost of Revenue TTM 75.0m) / Revenue TTM)
Gross Margin QoQ = 50.45% (prev 43.35%)
Tobins Q-Ratio = 0.12 (Enterprise Value 138.7m / Total Assets 1.18b)
Interest Expense / Debt = 463.5% (Interest Expense 8.07m / Debt 1.74m)
Taxrate = 21.0% (US default 21%)
NOPAT = 5.98m (EBIT 7.57m * (1 - 21.00%))
Current Ratio = 22.45 (Total Current Assets 922.2m / Total Current Liabilities 41.1m)
Debt / Equity = 0.00 (Debt 1.74m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = -37.86 (Net Debt -782.4m / EBITDA 20.7m)
Debt / FCF = 136.3 (negative FCF - burning cash) (Net Debt -782.4m / FCF TTM -5.74m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.06% (Net Income 36.1m / Total Assets 1.18b)
RoE = 3.36% (Net Income TTM 36.1m / Total Stockholder Equity 1.07b)
RoCE = 0.70% (EBIT 7.57m / Capital Employed (Equity 1.07b + L.T.Debt 1.74m))
RoIC = 0.56% (NOPAT 5.98m / Invested Capital 1.07b)
WACC = 8.39% (E(961.1m)/V(962.8m) * Re(8.41%) + (debt cost/tax rate unavailable))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.54%
Fair Price DCF = unknown (Cash Flow -5.74m)
EPS Correlation: 56.96 | EPS CAGR: 15.56% | SUE: -0.24 | # QB: 0
Revenue Correlation: 40.69 | Revenue CAGR: 2.92% | SUE: -0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=-0.007 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=+0.003 | Revisions Net=+0 | Growth EPS=+2576.9% | Growth Revenue=+31.7%